Placebo therapy of benign prostatic hyperplasia: A 2 5-month study

British Journal of Urology

Volumn 81, Issue 3, 1998, Pages 383-387

  Nickel, J C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Benign prostatic hyperplasia; Finasteride; Prostate

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SIDE EFFECT; SYMPTOM; TIME; TRANSRECTAL ULTRASONOGRAPHY; URINE FLOW RATE; URINE RETENTION;

AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY RETENTION; URINATION;

EID: 0031870068     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1998.00554.x     Document Type: Article

References (11)

1. Walsh PC. Benign prostatic hyperplasia: Etiological considerations. In Kimbai FA, Buhl AE, Carter DB. eds. New Approaches to the Study of Benign Prostatic Hyperplasia. Progress in Clinical and Biological Research Vol. 145. New York: Alan R. Liss Inc, 1984: 1-25
2. Roehrborn CG. The placebo effect in the treatment of benign prostatic hyperplasia. In Kirby R, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, eds, Textbook of Benign Prostatic Hyperplasia. Oxford: Isis Medical Media Ltd, 1996: 239-58
3. Nickel JC. Fradet Y, Boake RC et ai.Efficacy and safety of flnasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc ] 1996; 155: 1251
4. Bolognese JA. Kozloff RC. Kunik SC, Grino PB, Patrick DL, Stoner E. Validation of a symptoms questionnaire for benign prostatic hyperplasia. The Prostate 1992; 21: 291-9
5. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, flnasteride, or both in benign prostatic hyperplasia. New Eng J Med 1996; 335: 533-9
6. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologie intervention. The Prostate 1990; 3: 1-7
7. Bernier P, Montoya JD, Sech SA et al. 'Placebo effects' regarding peak flow rates and symptom scores in BPH trials are partially artefacts due to exclusion criteria. / Urol 1997; 157: 316A
8. McConnell JD, Barry MJ, Bruskewitz RC et al Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline, Number 8, Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1994
9. Barry B], Fowler FJ Jr, Bin L, Pitts JC, Harris CJ, Mullery AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. / Urol 1997; 157: 10-5
10. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with flnasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405
11. Beecher HK. The powerful placebo. JAMA 1955: 159: 1602-6